Celebrity Inventors
Glam girl Heddy Lamar may have used her good looks to good effect on the silver screen, but she put her smarts to better use as an inventor. During World War II, she co-patented a frequency-switching system for torpedo guidance that was considered years ahead of its time.
PatentStorm News
Make the Most of Our Site
See this month's Top Inventors and Most Cited Patents.
Stay on top of the latest innovations by subscribing to an RSS feed.
Registered users: Manage your profile.
| Number | Title | Issue Date |
| 8003656 | 2-phenoxy pyrimidinone analogues 2-Phenoxy pyrimidinone analogues are provided, of the Formula: wherein variables are as described herein. Such compounds are ligands that may be used to modulate specific receptor activity in vivo or in vitro, and are parti... | 08/23/2011 |
| 7932258 | Use of a partially neutralized, anionic (meth) acrylate copolymer as a coating for the production of a medicament pharmaceutical form releasing active substance at reduced pH values The invention relates to the use of a partially neutralized, anionic (meth)acrylate copolymer comprising radically polymerized units of 25 to 95 percent by weight of C1 to C4 alkyl esters of acrylic or methacrylic acid and 5 to 75 percent by we... | 04/26/2011 |
| 7354924 | Composition and antiviral activity of substituted azaindoleoxoacetic piperazine derivatives This invention provides Compounds I having drug and bio-affecting properties, their pharmaceutical compositions and method of use. In particular, the invention is concerned with azaindoleoxoacetyl piperazine derivatives. These compounds possess unique antiviral acti... | 04/08/2008 |
| 7335654 | Phosphodiesterase 4 inhibitors PDE4 inhibition is achieved by novel compounds of the Formula I: wherein R1 and R2 are as defined herein. ... | 02/26/2008 |
| 7326694 | Methods of optimizing drug therapeutic efficacy for treatment of immune-mediated gastrointestinal disorders The present invention provides a method of optimizing therapeutic efficacy and reducing toxicity associated with 6-mercaptopurine drug treatment of an immune-mediated gastrointestinal disorder such as inflammatory bowel disease. The method of the invention includes ... | 02/05/2008 |
| 7285557 | Pyrimidinones as melanin concentrating hormone receptor 1 A compound of formula (Ia) comprising a pharmaceutically acceptable salt or solvate thereof, formulations, processes of preparing, and methods of administering to mammals are provided ... | 10/23/2007 |
| 7256196 | Purine cytokine inhibitors The present invention relates to 2,8,9-substituted purines which inhibit the extracellular release of inflammatory cytokines, said cytokines responsible for one or more human or higher mammalian disease states. The present invention further relates to compositions c... | 08/14/2007 |
| 7253175 | Method for treating athlete's foot A method of treating a patient having a fungal infection comprises administering an effective fungal infection treatment amount of an antiviral agent, such as valacyclovir, to eliminate the symptoms of the fungal infection. ... | 08/07/2007 |
| 7253154 | Substituted thiazolopyrimidines as xanthine oxidase inhibitors The invention relates to compounds of the following formula (I) or their salts: in which R1 represents OR4 or others, in which R4 is an alkyl group having 1-8 carbon atoms which m... | 08/07/2007 |
| 7247639 | A1 adenosine receptor antagonists The present invention provides novel adenosine receptor antagonists, more particularly, A1 adenosine receptor antagonists of formula (I). Pharmaceutical compositions comprising an A1 adenosine receptor antagonist of formula (I) and a pharmaceut... | 07/24/2007 |
| 7241890 | Purine analogs having HSP90-inhibiting activity Novel purine compounds of Formula I. and tautomers, pharmaceutically acceptable salts, and prodrugs thereof, wherein X is S, S(O), or S(O)2; and O is selected from alkyl, cycloalkyl, arylalkyl, aryl, h... | 07/10/2007 |
| 7211667 | Antagonists of the magnesium binding defect as therapeutic agents and methods for treatment of abnormal physiological states This invention provides a class of therapeutic compounds and methods for the treatment of mammals with physiological disorders, such as for example a frequently occurring type of essential hypertension, which are critically associated with the decreased binding of m... | 05/01/2007 |
| 7115614 | Method of treating brain ischemia The present invention relates to a method of treating brain ischemia in which a xanthine derivative represented by formula (I): or a pharmaceutically acceptable salt thereof, as an active ingredient, is administe... | 10/03/2006 |
| 7105497 | Methods of optimizing drug therapeutic efficacy for treatment of immune-mediated gastrointestinal disorders The present invention provides a method of optimizing therapeutic efficacy and reducing toxicity associated with 6-mercaptopurine drug treatment of an immune-mediated gastrointestinal disorder such as inflammatory bowel disease. The method of the invention includes ... | 09/12/2006 |
| 7098237 | Remedies for ischemia reperfusion injury A composition for treating or preventing ischemia reperfusion injury which contains an sPLA2 inhibitor as an active ingredient. ... | 08/29/2006 |
| RE39112 | Purine derivatives and adenosine A2 receptor antagonists serving as preventives/remedies for diabetes The present invention provides a preventive or therapeutic agent of a new type for diabetes mellitus and diabetic complications on the basis of an adenosine A2 receptor antagonist action. A purine compound represented by the formula (I), its pharmacologically... | 05/30/2006 |
| 6962921 | Dementia remedies containing 2-aryl-8-oxodihydropurine derivatives as the active ingredient Medicines for treatment or prevention of dementia comprising 2-aryl-8-oxodihydropurine derivatives of the formula (I): wherein W is H, C1-6 alkyl, halogen, C1-6 alkoxy, or the like; X is H, C... | 11/08/2005 |
| 6936618 | Cystic fibrosis medicaments The use of a type V cyclic nucleotide phosphodiesterase inhibitor for the preparation of a medicament for the treatment of cystic fibrosis. ... | 08/30/2005 |
| 6906190 | Inhibitors for de novo-RNA polymerases and methods of identifying targets for same A polymerase inhibitor has first moiety coupled to a second moiety via an optional linker in which the first moiety binds to an initiation nucleotide binding site of a polymerase and forms at least two hydrogen bonds with an RNA template strand that is associated wi... | 06/14/2005 |
| 6894040 | Xanthine phosphodiesterase V inhibitors A xanthine phosphodiesterase V inhibitor having the formula (I), with the variables defined herein, which is especially useful for treating male (erectile) and female sexual dysfunction and other physiological disorders: | 05/17/2005 |
| 6894045 | Tetrahydropurinones and derivatives thereof as corticotropin releasing factor receptor ligands Compounds provided herein are novel substituted tetrahydropurinones of Formula (I): wherein R3 is aryl substituted with 0-5 XAr or heteroaryl substituted with 0-4 XhAr. Such compounds a... | 05/17/2005 |
| 6790841 | 2-hydroxymethylcyclopropylidenemethylpurines and -pyrimidines as antiviral agents Compounds which are active against viruses have the following Formulas: wherein B is a purine or pyrimidine heterocyclic ring and is preferably selected from the group consisting of 6-aminopurine (adenine), 2,6-diaminopu... | 09/14/2004 |
| 6770645 | Pharmaceutically active compounds Compound of general formula I: wherein R1, R2, R3, R4, X, Y and R5 have the meanings given herein which are useful in the curative and prophylactic treatment of a me... | 08/03/2004 |
| 6747016 | Substituted purine derivatives as inhibitors of cell adhesion The present invention relates to compounds of formula (I), in which B, D, E, G, X, Y, Z, R1, R2 and s have the meanings indicated in the claims, their physiologically tolerable salts and their prodrugs. The compounds of formula (I) are valuable... | 06/08/2004 |
| 6734187 | Purine derivatives and medicaments comprising the same as active ingredient Purine derivatives represented by the following formula and salts thereof: wherein R1 represents a C1-C4 alkyl group or difluoromethyl group; R2 represents tetrahydrofuranyl gr... | 05/11/2004 |
| 6693105 | Hydroxyl-containing compounds Disclosed are therapeutic compounds having the formula: including resolved enantiomers, diastereomers, hydrates, salts, solvates or mixtures thereof where j is an integer from one to three. The core moiety is a bicyclic ring structure having at least one heter... | 02/17/2004 |
| 6630478 | Methods for treatment of drug-induced peripheral neuropathy A method of treating drug-induced peripheral neuropathy comprising administering to a patient with drug-induced peripheral neuropathy an effective quantity of N-4-carboxaphenyl-3-(6-oxohydropurin-9-yl)propananide AIT-082, is disclosed. Peripheral ner... | 10/07/2003 |
| 6630490 | Methods for treatment of disease-induced peripheral neuropathy and related conditions A method of treating disease-induced peripheral neuropathy comprises administering to a patient with disease-induced peripheral neuropathy an effective quantity of a purine derivative or analogue, a tetrahydroindolone derivative or analogue, or a pyrimidi... | 10/07/2003 |
| 6599907 | Cystic fibrosis medicaments A method of treating cystic fibrosis in a patient comprising: administering to said patient an effective amount of a type V cyclic nucleotide phosphodisterase inhibitor, wherein said inhibitor is a compound of formula (I): ##STR1## wherein A is a five- or six... | 07/29/2003 |
| 6593332 | Pharmaceutically active compounds There is provided compounds of formula IA and of formula IB, ##STR1## wherein R1, R2, R3, Het1 and X have meanings given in the description, which are useful in the curative and prophylactic treatment of medical... | 07/15/2003 |
| 6586439 | Pharmaceutically active compounds There is provided compounds of formula IA and of formula IB, ##STR1## wherein R1, R2, R3, Het1 and X have meanings given in the description, which are useful in the curative and prophylactic treatment of medical... | 07/01/2003 |
| 6579868 | Purine derivatives and adenosine A2 receptor antagonists serving as preventives/remedies for diabetes The present invention provides a preventive or therapeutic agent of a new type for diabetes mellitus and diabetic complications on the basis of an adenosine A2 receptor antagonistic action. A purine compound represented by the formula (I), its pharmacologicall... | 06/17/2003 |
| 6548490 | Transmucosal administration of phosphodiesterase inhibitors for the treatment of erectile dysfunction A method is provided for treating erectile dysfunction in a mammalian male individual. The method involves the transmucosal administration of a phosphodiesterase inhibitor or a pharmaceutically acceptable salt, ester, amide or derivative thereof, within t... | 04/15/2003 |
| 6518277 | Inhibitors of human phosphatidylinositol 3-kinase delta Methods of inhibiting phosphatidylinositol 3-kinase delta isoform (PI3Kδ) activity, and methods of treating diseases, such as disorders of immunity and inflammation, in which PI3Kδ plays a role in leukocyte function are disclosed. Preferably, the method... | 02/11/2003 |
| 6514980 | Nucleoside analogs in combination therapy of herpes simplex infections A pharmaceutical product comprising a nucleoside analogue active against herpes simplex virus, such as acyclovir/valaciclovir or penciclorivir/famciclovir, and an immunosuppressant, as a combined preparation for simultaneous, separate or sequential use in... | 02/04/2003 |
| 6486166 | Suppression of cyclin kinase 2 activity for prevention and treatment of DNA viral infections An important aspect of the present invention is a method for inhibiting proliferation of a DNA virus dependent upon events associated with cell proliferation for replication. The DNA virus includes any of the herpesvirus family, and most particularly huma... | 11/26/2002 |
| 6476037 | L-arginine and phosphodiesterase (PDE) inhibitor synergism This invention pertains to the discovery that L-arginine and type V phosphodiesterases act synergistically to inhibit vasospasm and/or to induce vasodilation. Methods are provided using combinations of L-arginine and type V phosphodiesterase inhibitors in... | 11/05/2002 |
| 6462044 | Nitrosated and nitrosylated phosphodiesterase inhibitors, compositions and methods of use The present invention describes novel nitrosated and/or nitrosylated phosphodiesterase inhibitors, and novel compositions containing at least one nitrosated and/or nitrosylated phosphodiesterase inhibitor, and, optionally, one or more compounds that donat... | 10/08/2002 |
| 6440982 | Pharmaceutically active compounds There is provided compounds of formula IA and of formula IB, ##STR1## wherein R1, R2, R3, Het1 and X have meanings given in the description, which are useful in the curative and prophylactic treatment of medical... | 08/27/2002 |
| 6440981 | Method for inhibiting neoplastic cells and related conditions by exposure to 2,9-disubstituted purin-6-ones A method for inhibiting the growth of neoplastic cells by exposure to 2,9-disubstituted purin-6-ones.... | 08/27/2002 |
